Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1400

Sort by

Sort Order Select

Journal Articles

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Blood (2020) 136 (2): 171–182.

https://doi.org/10.1182/blood.2019004596

Published: 2020

Includes: Supplemental data

Journal Articles

Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice

Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Yoshinori Ozono, Yuki Tahira, Takako Yokomizo-Nakano, Sho Kubota, Masaya Ono, Kazuhiko Ikeda, Masaaki Sekine, Keiichi Akizuki, Kenichi Nakamura, Tomonori Hidaka, Yoko Kubuki, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata, Goro Sashida, Kazuya Shimoda

Blood (2020) 136 (1): 106–118.

https://doi.org/10.1182/blood.2019003358

Published: 2020

Includes: Supplemental data

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Jessica L. Bridgford, Su Min Lee, Christine M. M. Lee, Paola Guglielmelli, Elisa Rumi, Daniela Pietra, Stephen Wilcox, Yash Chhabra, Alan F. Rubin, Mario Cazzola, Alessandro M. Vannucchi, Andrew J. Brooks, Matthew E. Call, Melissa J. Call

Blood (2020) 135 (4): 287–292.

https://doi.org/10.1182/blood.2019002561

Published: 2020

Includes: Supplemental data

Journal Articles

Unexpected lymph node finding in a patient with essential thrombocythemia

Daniel A. Hale, John R. Krause

Blood (2020) 135 (2): 154.

https://doi.org/10.1182/blood.2019002036

Published: 2020

Journal Articles

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Murtadha Al-Khabori, MD, Shoaib Al-Zadjali, PhD, Iman Al Noumani, Khalil Al Farsi, Salam Al-Kindi, MD, Mohamed Al Huneini, MD, Naglaa Fawaz, MBBChir, MMSc, PhD, Al Lamki Sulayma, MD, Mahdiya Pir Al Bulushi, MD FRCPC, Khalid Al Hashmi, MD, Muna Al Tarshi, MD, Muhanna Almusalhi

Blood (2019) 134 (Supplement_1): 5383.

https://doi.org/10.1182/blood-2019-128309

Published: 2019

Journal Articles

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Blood (2019) 134 (Supplement_1): 4238.

https://doi.org/10.1182/blood-2019-126967

Published: 2019

Journal Articles

Exploring the Basis and Acceptability of Practice Variation Among Thrombosis Medicine Specialists: A Mixed-Methods Study

Leslie Skeith, MD, Carol Gonsalves, MD MMEd, Alan Schwartz, PhD, Laura Hirshfield, PhD, Matthew Lineberry, PhD

Blood (2019) 134 (Supplement_1): 5791.

https://doi.org/10.1182/blood-2019-123284

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis: A Single Institution Experience

Sajjad Akbar Bhatti, MBBS, Abdulraheem Yacoub, MD, Anurag K. Singh, MD

Blood (2019) 134 (Supplement_1): 5740.

https://doi.org/10.1182/blood-2019-129505

Published: 2019

Journal Articles

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Thomas G. Knight, MD, Myra Robinson, MS, Jing Ai, MD PhD, Brittany K Ragon, MD, Rhonda Davis, RN, BSN, Cindy Shiflett, LPN, Erica Ruston, RN, BSN, Hailey Glover, RN, BSN, Jigar Trivedi, MSc, PharmD, Belinda R Avalos, MD, Jonathan M. Gerber, MD, James T Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 2099.

https://doi.org/10.1182/blood-2019-128858

Published: 2019

Journal Articles

Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma

Johanne Marie Holst, MD, Martin Bjerregaard Pedersen, MD, PhD, Marcus C Hansen, MSc, Trine Lindhardt Plesner, Henrik Frederiksen, MD, Michael Møller, Stephen Hamilton-Dutoit, Peter Noergaard, Bo Kok Mortensen, Danilo Fiore, PhD, Chao Wang, Weiwei Zhang, Wayne Tam, MD PhD, Maja Ludvigsen, MSc, PhD, Wing C. Chan, MD, Giorgio Inghirami, MD, Francesco d'Amore, MD

Blood (2019) 134 (Supplement_1): 2776.

https://doi.org/10.1182/blood-2019-131465

Published: 2019

Journal Articles

Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey

Hisashi Ishida, MD PhD, Takeo Sarashina, MD PhD, Risa Matsumura, Katsutsugu Umeda, MD, PhD, Tetsuo Mitsui, MD PhD, Naoto Fujita, MD PhD, Daisuke Tomizawa, MD PhD, Kevin Y Urayama, PhD MPH, Yasushi Ishida, MD PhD, Takashi Taga, MD PhD, Masatoshi Takagi, MD PhD, Souichi Adachi, MD PhD, Atsushi Manabe, MD PhD, Toshihiko Imamura, MD PhD, Katsuyoshi Koh, MD, Akira Shimada, MD PhD

Blood (2019) 134 (Supplement_1): 2958.

https://doi.org/10.1182/blood-2019-123429

Published: 2019

Journal Articles

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Keiji Minakawa, Koki Ueda, MD PhD, Osamu Nakajima, Tetsuro Yokokawa, MD, Yusuke Kinishima, MD, Tomofumi Misaka, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yasuchika Takeishi, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2019) 134 (Supplement_1): 2964.

https://doi.org/10.1182/blood-2019-124575

Published: 2019

Journal Articles

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Tobias Ronny Haage, MD, Andreas Johann Müller, Priyadharshini Arunachalam, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2965.

https://doi.org/10.1182/blood-2019-122660

Published: 2019

Journal Articles

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Peter Müller, PhD, Bärbel Edelmann-Stephan, PhD, Fabian Richter, PhD, Klaus Pfizenmaier, PhD, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2966.

https://doi.org/10.1182/blood-2019-127997

Published: 2019

Journal Articles

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Stephanie Berg, DO, Manuel O. Diaz, MD, Sucha Nand, MD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 2969.

https://doi.org/10.1182/blood-2019-124805

Published: 2019

Journal Articles

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

Ken-Hong Lim, MD, Yu-Cheng Chang, MD, Yi-Hao Chiang, MD, Huan-Chau Lin, MD, Ling Huang, MSc, Wei-Ting Wang, MSc, Ying-Wen Su, MD, PhD, Ming-Chih Chang, MD, Yi-Fang Chang, MD PhD, Caleb Gon-Shen Chen, MD PhD

Blood (2019) 134 (Supplement_1): 2970.

https://doi.org/10.1182/blood-2019-124420

Published: 2019

Journal Articles

Distinct Bone Marrow Microenvironment Abnormalities in MDS and MPN with Fibrosis

Cao Sy Luan, MS, Yoshiaki Takahoko, MS, Hidekazu Nishikii, MD PhD, Naoshi Obara, MD PhD, Tatsuhiro Sakamoto, MD PhD, Takayasu Kato, MD PhD, Keiichiro Hattori, MD PhD, Ryota Matsuoka, MD PhD, Shingo Sakashita, MD PhD, Yasuhito Nannya, MD PhD, Hideki Makishima, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Seishi Ogawa, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 2976.

https://doi.org/10.1182/blood-2019-129423

Published: 2019

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Unexpected lymph node finding in a patient with essential thrombocythemia

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Exploring the Basis and Acceptability of Practice Variation Among Thrombosis Medicine Specialists: A Mixed-Methods Study

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Outcomes of Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis: A Single Institution Experience

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma

Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

Distinct Bone Marrow Microenvironment Abnormalities in MDS and MPN with Fibrosis

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only